2

3

1

2

3

4


5

WHAT IS CLAIMED IS:

1		1.	A method of screening for a carrier-type	transport protein and/or a
2	ligand thereto.	compr	sing:	

- (a) providing a library comprising different complexes, each complex
 comprising a compound and a reporter, the compound varying between different complexes;
- 5 (b) providing a population of cells, one or more of which expresses one or 6 more carrier-type transport proteins;
- 7 (c) contacting the population of cells with a plurality of complexes from 8 the library; and
 - (d) detecting a signal from the reporter of a complex that is bound to a cell or internalized within a cell, the signal providing an indication that a complex whose reporter generated the signal comprises a compound that is a ligand for a carrier-type transport protein.
 - 2. The method of claim 1, wherein the reporter preferentially generates the signal once the reporter is internalized within the cell, the signal thus providing an indication that a complex whose reporter generated the signal comprises a compound that is a potential substrate for a carrier-type transport protein.
 - 3. The method of claim 2, wherein the reporter contains a cleavable site and the reporter is cleaved at the cleavable site after the complex is internalized within the cell.
 - 4. The method of claim 2, wherein reporter comprises an agent that causes a morphological change upon internalization within a cell, and if a compound complexed with the reporter is a substrate for the carrier-type protein, the complex is transported by the carrier-type protein into a cell expressing the carrier-type protein, whereby the agent triggers a detectable morphological change in the cell.
- 1 5. The method of claim 3, wherein the agent inhibits cytoskeleton 2 formation.

signal.



- 7. The method of claim 6, wherein the reporter further comprises a cleavable linker that links the fluorophore and quencher moiety, the cleavable linker being cleaved after entry of the reporter into the cell.
 - 8. The method of claim 6, wherein the fluorophore and quencher moiety are joined via a linker that contains a site cleavable by an enzyme, and the population of cells express the enzyme.
 - 9. The method of claim 8, wherein the enzyme is an endogenous enzyme.
 - 10. The method of claim 8, wherein the enzyme is expressed from an exogenous sequence harbored by the population of cells.
 - 11. The method of claim 8, wherein the enzyme is a hydrolase.
 - 12. The method of claim 2, wherein the reporter comprises a detection moiety disposed to interact with an intracellular agent, the cells have the intracellular agent, and if a compound complexed with the reporter is a substrate for the carrier-type protein, the complex is transported by the carrier-type transport protein into a cell expressing the carrier-type transport protein, whereby the detection moiety interacts with the intracellular agent to generate a detectable signal, and the detection step comprises detecting the detectable signal.
- 13. The method of claim 12, wherein the detection moiety is a nucleic-acid binding dye and the intracellular agent is a nucleic acid.
- 14. The method of claim 2, wherein the reporter comprises a substrate for an enzyme, and if a compound complexed with the reporter is a substrate for the carrier-type protein, the complex is transported by the carrier-type transport protein into a cell expressing

2

1

2

3

1

5

1

2

3

4

5

1

2

1

2

- the carrier-type protein and the enzyme, whereby the enzyme metabolizes the enzyme substrate to form a detectable product, and the detecting step comprises detecting the
- 6 detectable product.
- 15. The method of claim 14, wherein the enzyme is selected from the
 2 group consisting of luciferase, alkaline phosphatase, β-galactosidase, and β-glucouronidase.
- 1 16. The method of claim 15, wherein the reporter comprises luciferin, and wherein the population of cells express luciferase, and the luciferase metabolizes the luciferin to generate the detectable product.
 - 17. The method of claim 16, wherein the luciferin is derivatized to bear a polar moiety to reduce passive uptake of complex.
 - 18. The method of claim 17, wherein luciferin is joined to the complex via a cleavable site and an intracellular enzyme cleaves luciferin from the complex before luciferin can be metabolized by luciferase.
 - 19. The method of claim 2, wherein the contacting step results in at least one complex being internalized within a cell through the activity of the carrier-type transport protein, the reporter promotes aggregation of subunits of a multimeric enzyme expressed within the population of cells, and the enzyme catalyzes production of a product that generates a detectable signal, the detecting step comprising detecting the detectable signal.
 - 20. The method of claim 2, wherein the contacting step results in at least one complex being internalized in a cell through the activity of the carrier-type transport protein, the reporter promotes transcription from a promoter within a cell resulting in expression of an expression product that generates a detectable signal, and the detecting step comprises detecting the detectable signal.
 - 21. The method of claim 20, wherein the expression product is an enzyme that catalyzes the production of the detectable signal.
 - 22. The method of claim 2, wherein the contacting step results in at least one complex being internalized in at least one cell through the activity of the carrier-type transport protein, the reporter confers a selective advantage within the cell(s), and the

4

5

1

2

3

4

5

6

1

2

3

4

- detecting step comprises propagating the population of cells under conditions that enrich for cell(s) on which the selective advantage has been conferred.

 The method of claim 1, wherein the contacting step results in at least one complex being internalized in a cell through the activity of the carrier-type transport
 - one complex being internalized in a cell through the activity of the carrier-type transport protein, and the method further comprises washing cells to remove unincorporated complexes before the detecting step, whereby signal from reporter internalized within the cell is preferentially detected.
 - 24. The method of claim 1, wherein the contacting step results in at least one complex being internalized in a cell through the activity of the carrier-type transport protein, the reporter is a fluorescent molecule, and the method further comprises contacting cells with a fluorescence quencher incapable of entering the cells to quench fluorescence of unincorporated complexes before the detecting step, whereby signal from reporter internalized within the cell is preferentially detected.
 - SAR)
- 25. The method of claim 1, wherein
- (a) the population of cells comprise different cells that are located in a single reaction vessel;
- (b) contacting results in at least one complex being bound to or internalized within one of the cells; and
- 6 (c) detecting comprises detecting the signal from the at least one complex.
- 1 26. The method of claim 25, wherein
- 2 (a) the different cells comprise test cells and counterpart control cells, the 3 test cells expressing one of the one or more carrier-type transport proteins while the control cells fail to express the transport protein expressed by the test cells;
- 5 (b) the at least one complex is bound to or internalized within one of the 6 test cells; and
- 7 (c) detecting further comprises detecting signal, if any, from the control 8 cells.

1	27.	The method of claim, 25, further comprising:
2	(e) complexes; and	separately contacting the different cells with each of the plurality of
4 5	(f) is bound or internaliz	determining the identity of the cell(s) to which the at least one complex ed within.
1 2	28. distinguishable chara	The method of claim 25, wherein different cells have different cteristics, and the method further comprises:
3	(e) bound or internalized	determining the identity of the cell to which the at least one complex is within from its distinguishable characteristic.
1 2	29.	The method of claim 28, wherein the distinguishable characteristics are phologies.
1 2	30. different stains on the	The method of claim 28, wherein the distinguishable characteristics are cells.
1 2	31. different markers loc	The method of claim 28, wherein the distinguishable characteristics are ated at the surface of the cells.
1 2 3	• •	The method of claim 31, wherein the different markers are different tepitopes being differentially stained with antibodies specific for the tibodies for different epitopes bearing different labels.
1 2	33. is expressed from an	The method of claim 32, wherein one or more of the different epitopes endogenous nucleic acid sequence.
1 2	34. is expressed from an	The method of claim, 32, wherein one or more of the different epitopes exogenous nucleic acid sequence.
1	35.	The method of claim 1, wherein
2	(a)	the population of cells are contained in a single reaction vessel; and

3	(b)	contacting comprises contacting the cells within the reaction vessel	
4	with a plurality of di	fferent complexes, different complexes comprising different compounds,	
5	whereby at least one complex is bound to or internalized within the cells; and		
6	(c)	detecting comprises detecting signal from the at least one complex.	
1	36.	The method of claim 35 further comprising:	
2	(d)	separately contacting the population of cells within different reaction	
3	vessels with the diffe	erent complexes such that cells within the same reaction vessel receive	
4	the same complex w	hile cells in at least some of the different reaction vessels receive	
5	different complexes; and		
6	(e)	determining the identity of the at least one complex.	
1	37.	The method of claim 35, wherein	
2	(a)	the reporter varies between different complexes and different reporters	
3	are disposed to gene	rate different signals; and	
4	(b)	detecting comprises detecting the signal from the reporter of the at	
5	least one complex, the	ne signal from the at least one complex providing an indication of the	
6	identity of the comp	ound of the at least one complex.	
1	38.	The method of claim 37, wherein different reporters comprise different	
2	labels, the different l	abels selected from the group consisting of a radiolabel, a mass label, a	
3	spin label, a fluoropl	nore, a chromophore and a luminescent moiety.	
1	39.	The method of claim 37, wherein different reporters comprise	
2	substrates for differe	ent enzymes expressed within the one or more cells.	
1	40.	The method of claim 37, wherein the population of cells is a plurality	
2	of different cells, dif	ferent cells having different distinguishable characteristics, and further	
3	comprising determin	ing the identity of the cell to which the at least one complex is bound or	
4	internalized from its distinguishing characteristic.		
1	41.	The method of claim 1, wherein detecting comprises detecting a signal	

from a reporter internalized within the one or more cells to identify at least one complex that

10

(g)

3	is internalized within the one or more cells, the compound complexed to the internalized		
4	complex being a substrate potentially able to transport an agent into cells expressing a carrier		
5	type transport protein, the method further comprising:		
6	(e) providing a modified complex, the modified complex comprising the		
7	compound identified in the detecting step (d) and an agent;		
8	(f) contacting one or more cells with the modified complex; and		
9	(g) determining whether the modified complex is internalized within one		
10	of the one or more cells by detecting the modified complex within the one or more cells, such		
11	detection providing an indication that the compound can serve as a substrate for transporting		
12	agents into cells expressing carrier-type transport proteins.		
1	42. The method of claim 41, wherein the agent is a pharmaceutical agent.		
1	43. The method of claim 42, wherein the reporter is attached to the		
2	complex of the at least one complex at an attachment site and the pharmaceutical agent		
3	replaces the reporter in the modified complex such that the pharmaceutical agent is attached		
4	to the attachment site in the modified complex.		
1	44. The method of claim 43, wherein the providing step comprises		
2	synthesizing the modified complex.		
1	45. The method of claim 43, wherein the modified complex further		
2	comprises a reporter attached at a site other than the attachment site.		
1	46. The method of claim 1, wherein contacting results in at least one		
2	complex being internalized in a cell, detecting comprises detecting signal from the reporter of		
3	the at least one complex and the method further comprises		
4	(e) determining the identity of the compound in the at least one complex		
5	detected in step (d);		
6	(f) providing a focused library, the focused library comprising a plurality		
7	of complexes, each complex in the focused library comprising a compound that is a variant of		
8	the compound identified in step (e):		

focused library, the one or more cells expressing a carrier-type transport protein; and

contacting one or more cells with one or more of the complexes of the

11	(h	detecting a signal from a reporter of a complex internalized within one	
12	of the one or mor	e cells, the signal providing an indication that the compound of the	
13	internalized complex is a substrate for a carrier-type transport protein.		
1	47	The method of claim 1, wherein the population of cells has been	
2		a DNA library encoding the one or more transport proteins.	
۷	transformed with	a DIVA library encouning the one of more transport proteins.	
1	48	The method of claim 47, further comprising:	
2	(e)	isolating a cell that has bound the reporter or internalized the reporter;	
3 .	and		
4	(f)	isolating a DNA molecule encoding a carrier-type transport protein	
5	from the isolated	cell to identify the carrier-type transport protein that exhibits activity with	
6	the compound of the complex that is bound to or internalized within the isolated cell.		
7	•	•	
•			
1	49	The method of claim 1, wherein the carrier-type transport protein is	
2	selected from the	group of an amino acid transporter, a dipeptide transporter, an oligopeptide	
3	transporter, a sim	ple sugar transporter, a bile acid transporter, a vitamin transporter, a	
4	phosphate transp	orter, a monocarboxylic acid transporter, an organic anion transporter, an	
5	organic cation transporter, fatty acid transporter, a nucleoside transporter, and a ABC		
6	transporter.		
	5.0	The most of a Calabar 40 and amin the transmission is called a frame	
1	50	• •	
2	the group consisting of PEPT1, sodium-dependent glucose transport protein (SGLT1), liver		
3	bile acid transpor	ter (NTCP) and ileal bile acid transporter (ASBT).	
1	51	. The method of claim 1, wherein the one or more carrier-type proteins	
2	are endogenous p	proteins.	
1	52	The method of claim 1, wherein the one or more carrier-type proteins	
2	are expressed fro	m an exogenous sequence harbored by the population of cells.	
	_	•	
1	50%/ 53		
2	selected from the	group consisting of Chinese hamster ovary (CHO) cells, VERO cells,	

3/	4	HT29 cells.					
/	1	54.	The method of claim 53, wherein the cells are treated to yield				
	2	membrane preparations or vesicles and the complexes are contacted with the membrane					
	3	preparations or ve	sicles.				
	1	SUB 55.	The method of claim 1, wherein the test compound is directly joined to				
	2	the reporter via a	chemical bond.				
	1	56.	The method of claim 1, wherein the complex further comprises a linker				
	2	joining the test con	mpound and the reporter.				
	1	57.	The method of claim 1, wherein the linker contains a cleavage site.				
	1	58.	The method of claim 1, wherein the linker is a stable linker lacking a				
	2	cleavage site.					
W 113	1	59.	The method of claim 1, wherein the reporter is selected from the group				
======================================	2	consisting of a flu	orophore, a chromophore, a radioisotope, a magnetic particle, a mass label				
	3	and a spin label.					
	1	60.	The method of claim 59, wherein the reporter is a fluorophore.				
Ş	1	61.	The method of claim 1, wherein the detection step is performed by				
	2	brightfield, phase	contrast or fluorescence microscopy.				
	1	62.	The method of claim 1, wherein the detection step is performed using a				
	2	confocal microsco	pe.				
	1	63.	The method of claim 62, wherein the confocal microscope has multiple				
	2	wavelength detect	ion capability.				
	1	64	The method of claim 1, wherein the different compounds are				

HeLA cells, COS-7 cells, MDCK cells, HEK cells, CaCo-2 cells, HCT-8 cells, T84 cells and

65. The method of claim 1, wherein the different compounds are variants of a known substrate for a carrier-type transport protein.

2

1

2

compounds from a combinatorial library.

1	ı	66.	The method of claim 1, wherein the different compounds are small
2	molecules.		
1	,	67.	The method of claim 1, wherein the plurality of different compounds
2	are peptides.		
1		68.	The method of claim 1, wherein the population of cells of step (b)
2	comprise a test	popul	ation and the method further comprises
3		(e)	providing a population of control cells the same as the population of
4	test cells of step	p (b), e	except that the control cells fail to express the one or more carrier-
5	mediated transport proteins; and		
6	1	(f)	repeating steps (c) and (d) with the control cells, wherein a statistically
7		` '	in the signal from the reporter in the population of test cells relative to
8	the signal from	the co	ontrol cells provides a further indication that the complex whose reporter
9	generated the s	ignal c	comprises a compound that is a ligand for a carrier-type transport
10	protein.		
1		69.	A method of screening for a carrier-type transport protein and/or a
2	substrate theret	o, com	pprising:
3	1	(a)	providing one or more cells, each cell expressing a carrier-type
4	transport protei	n;	
5		(b)	contacting the one or more cells with one or more complexes, each
6	complex comp	rising a	a compound and a reporter; and
7		(c)	selectively detecting a signal from a reporter internalized within one or
8	more of the cel	ls as co	ompared to signal from reporter outside the cell to indicate that a
9	complex whose	e repor	ter generated the signal comprises a compound that is a substrate for a
10	carrier-type tra	nsport	protein.
1		70.	The method of claim 69, wherein the reporter comprises a fluorophore
2	and a quencher	moiet	y, and if a compound complexed with the reporter is a substrate for the
3	carrier-type tra	nsport	er protein, the complex is transported by the carrier-type transport
4	protein into a c	ell exp	pressing the carrier-type transporter protein, whereby the quencher
5	moiety become	es sena	rated from the fluorophore such that a fluorescent signal is emitted by

1.

2

6

7

8

9

10

1

2


3

4

5

- the fluorophore within the cell, and the detection step comprises detecting the fluorescent 6 7 signal.
- 1 71. The method of claim 69, wherein the contacting step results in at least 2 one complex being internalized in a cell, the reporter is a fluorophore that fluoresces upon 3 binding to a nucleic acid within the cell, which fluorescence is detected in the detecting step.
 - 72. The method of claim 69, wherein the reporter comprises a substrate for an enzyme, and if a compound complexed with the reporter is a substrate for the carrier-type protein, the complex is transported by the carrier-type transport protein into a cell expressing the carrier-type protein and the enzyme, whereby the enzyme metabolizes the substrate to form a detectable product, and the detecting step comprises detecting the detectable product.
 - 73. The method of claim 69, wherein the contacting step results in at least one complex being internalized in a cell, the reporter promotes aggregation of subunits of a multimeric enzyme expressed within the population of cells, and the enzyme catalyzes production of a product that generates a detectable signal, and detecting comprises detecting the detectable signal.
 - 74. The method of claim 69, wherein the contacting step results in at least one complex being internalized in a cell, the reporter promotes transcription of a promoter within a cell resulting in expression of an enzyme that catalyzes production of a product that generates a detectable signal, and detecting comprises detecting the detectable signal.
 - 75. A method of screening for a carrier-type transport protein and/or a ligand thereto, comprising:
- 3 (a) providing a plurality of different cells that are located within a single 4 reaction vessel, each cell expressing a carrier-type transport protein, and different cells 5 having different distinguishable characteristics;
 - (b) contacting the plurality of different cells with one or more complexes, each complex comprising a compound and a reporter, whereby at least one complex is bound to or internalized within one of the cells;
 - detecting a signal from the reporter of the at least one complex bound to or internalized within the cell in step (b); and

12	characteristic.	determining the identity of the cen in step (b) from its distinguishable	
1	76.	A method of screening for a carrier-type transport protein and/or a	
2	ligand thereto, comprising:		
3	(a)	providing one or more cells, each cell expressing a carrier-type	
4	transport protein, and	d located in a single reaction vessel;	
5	(b)	contacting the one or more cells with a plurality of different	
6	complexes, each con	nplex comprising a compound and a reporter, the compound and reporter	
7	varying between diff	erent complexes and different reporters disposed to generate different	
8	signals, whereby at least one complex is bound to or internalized within the one or more		
9	cells; and		
10	(c)	detecting the signal from the reporter of the at least one complex, the	
11	signal providing an i	ndication of the identity of the compound borne by the at least one	
12	complex.		
1	77.	A method of screening for a carrier-type transport protein and/or a	
2	substrate thereto, cor	mprising:	
3	(a)	providing one or more cells, each cell expressing a carrier-type	
4	transport protein;		
5	(b)	contacting the one or more cells with one or more complexes, each	
6	complex comprising	a compound and a reporter;	
7	(c)	detecting a signal from a reporter internalized within the one or more	
8	cells to identify at lea	ast one complex that is internalized within the one or more cells, the	
9	compound of the inte	ernalized complex being a substrate potentially disposed to transport a	
10	pharmaceutical agen	t into a cell via the activity of a carrier-type transport protein;	
11	(d)	preparing a modified complex, the modified complex comprising the	
12	compound identified	in step (c) and a pharmaceutical agent;	
13	(e)	repeating steps (a) and (b) with the modified complex: and	



- 1 78. A method of screening for a receptor-type transport protein and/or a ligand thereto, comprising:
- (a) providing a library comprising different complexes, each complex
 comprising a compound and a reporter, the compound varying between different complexes;
- 5 (b) providing a population of cells, one or more of which expresses one or 6 more receptor-type transport proteins;
- 7 (c) contacting the population of cells with a plurality of complexes from 8 the library; and
 - (d) detecting a signal from the reporter of a complex that is bound to a cell, internalized within a cell or has been transported through a cell, the signal providing an indication that a complex whose reporter generated the signal comprises a compound that is a ligand for a receptor-type transport protein.
 - 79. The method of claim 78, wherein the reporter comprises a fluorophore and a quencher moiety, and if a compound complexed with the reporter is a substrate for the receptor-type transporter protein, the complex is transported by the receptor-type transport protein into a cell expressing the receptor-type transporter protein, whereby the quencher moiety becomes separated from the fluorophore such that a fluorescent signal is emitted by the fluorophore within the cell, and the detection step comprises detecting the fluorescent signal.
 - 80. The method of claim 78, wherein the contacting step results in at least one complex being internalized within a cell through the activity of the receptor-type transport protein, the reporter comprises a nucleic-acid binding dye, and whereby the dye interacts with a nucleic acid within one of the cells to generate a detectable signal, and the detection step comprises detecting the detectable signal.

2

3

4 5

1

2

3 4

1 2

1

2

3


4


5

1

2

- 81. The method of claim 78, wherein the detection moiety is a nucleic-acid binding dye and the intracellular agent is a nucleic acid.
- 82. The method of claim 78, wherein the contacting step results in at least one complex being internalized within a cell through the activity of the receptor-type transport protein, the reporter comprises a substrate for an enzyme, the population of cells express the enzyme, and whereby the enzyme metabolizes the substrate to form a detectable product, and the detecting step comprises detecting the detectable product.
- 83. The method of claim 78, wherein the contacting step results in at least one complex being internalized within a cell through the activity of the receptor-type transport protein, the reporter promotes aggregation of subunits of a multimeric enzyme expressed within the population of cells, and the enzyme catalyzes production of a product that generates an optical signal, the detecting step comprising detecting the optical signal.
- 84. The method of claim 78, wherein the contacting step results in at lest one complex being internalized in a cell through the activity of the receptor-type transport protein, the reporter promotes transcription from a promoter within a cell resulting in expression of an enzyme that generates an optical signal, and the detecting step comprises detecting the optical signal.
- 85. The method of claim 78, wherein the contacting step results in at least one complex being internalized in at least one cell through the activity of the receptor-type transport protein, the reporter confers a selective advantage within the cell(s), and the detecting step comprises propagating the population of cells under conditions that enrich for cell(s) on which the selective advantage has been conferred.
 - 86. The method of claim 78, wherein
- the population of cells comprise different cells, the different (a) cells expressing different receptor-type transport proteins, having different distinguishable characteristics and being located in a single reaction vessel;
- 5 contacting results in at least one complex being bound to, 6 internalized within, or transported through one of the cells;





1 103. The method of claim 102, wherein the reporter is a substrate for an enzyme, the membrane is impregnated with the enzyme, and after transport of a complex through a cell, the enzyme metabolizes the reporter of the complex to generate a product generating an optical signal.


4

5

6


7

8



(a) introducing into a body compartment of an animal a population of complexes, each complex comprising a support, a test compound, and a reporter, the test compound varying between complexes; and

(b) recovering complexes by means of their reporter from a tissue or fluid of the animal after transport of at least some of the complexes through cells lining the body compartment.



the recovered complexes by similarity in chemical structure.



I	110.	The method of claim 117, further comprising ranking groups by	
2	number of members, the ranking providing an indication of the efficacy of compounds in a		
3	group as substrates of a transport protein in the cells lining the body compartment.		
1	119.	The method of claim 107, further comprising	
2	(c)	contacting recovered complexes with a population of polarized cells	
3	transformed with a I	ONA library at least some members of which encode potential transport	
4	proteins, the cells be	eing arranged as a monolayer on a membrane and the complexes	
5	contacting the apical side of the cells;		
6	(d)	detecting complexes transported through the polarized cells to the	
7	membrane by virtue of the reporter of the complexes;		
8	(e)	recovering polarized cells in proximity to the transported complexes;	
9	and		
10	(f)	clonally expanding the recovered polarized cells.	
1	120.	The method of claim 119, further comprising	
2	(g)	forming a monolayer of cells on a membrane for each of a plurality of	
3	clonally expanded recovered polarized cells;		
4	(h)	contacting each monolayer with another sample of recovered	
5	complexes from the animal; and		
6	(i)	recovering further recovered complexes that have been transported	
7	through the monolay	yers of cells, the complexes passing through a monolayer having	
8	complexes that are substrates for a receptor-type transport protein expressed by the cells in		
9	the monolayer.		
1	121.	The method of claim 119, further comprising	
2	(g)	recovering complexes contacted with one of the monolayers that are	
3	not transported thro	ugh the monolayer, and contacting the recovered complexes with a	
4	second monolaver.		

2

1 2

1

2





- 1 122. The method of claim 107, wherein the introducing step comprises 2 introducing a plurality of populations of complexes into the body compartment of the animal, 3 the different populations having different reporters, and the recovering step comprises 4 recovering a plurality of subpopulations of complexes, the different subpopulations having 5 the different reporters.
- 1 123. The method of claim 122, wherein each subpopulation is recovered by affinity chromatography using a different receptor for each different reporter.
- 1 124. The method of claim 122, further comprising ranking the recovered 2 subpopulations by number of members.
 - 125. The method of claim 122, wherein the different reporters give different optically detectable signals.
 - 126. The method of claim 125, wherein the different reporters are fluorescent molecules emitting at different wavelengths.
 - 127. A pharmaceutical composition comprising a nanoparticle, a drug within or linked to the nanoparticle and a ligand linked to or within the nanoparticle, the ligand being effective to promote cellular uptake and/or transport of the particle by receptor-type transport proteins.
- 1 128. The pharmaceutical composition of claim 127, wherein the ligand is 2 substrate for a receptor-type transport receptor.
- 1 129. The pharmaceutical composition of claim 127, further comprising a second ligand linked to or within the nanoparticle.
- 1 130. The pharmaceutical composition of claim 129, wherein the ligand 2 binds to a first cellular receptor, and the second ligand binds to a transport protein, which 3 binding results in internalization of the nanoparticle.
- 1 131. The pharmaceutical composition of claim 130, wherein the second 2 ligand is contained within the nanoparticle and is released on binding of the first ligand to the 3 cellular receptor.

target organelle.



1

Ä

1 The pharmaceutical composition of claim 129, wherein the ligand 132. 2 binds to a receptor-type transport protein, which binding results in internalization of the 3 nanoparticle, and the second ligand binds to a second transport protein within a cell that 4 effects basolateral trafficking of the internalized nanoparticle to the basolateral exterior of the 5 cell. 1 133. The pharmaceutical composition of claim 127, further comprising an 2 agent linked to or within the particle. 1 134. The pharmaceutical composition of claim 133, wherein the agent is a 2 buffering agent. The pharmaceutical composition of claim 133, wherein the agent is an 1 135. 2 antacid. 136. The pharmaceutical composition of claim 133, wherein the agent is a 1 2 lysing agent. 1 137. The pharmaceutical composition of claim 127, further comprising a 2 compound that after internalization of the nanoparticle into a cell targets the nanoparticle to a